| Samantha Brooks, | |
|
23 Hospital Dr Ste 102, Abilene, TX 79606-5270 | |
| (325) 238-9337 | |
| Not Available |
| Full Name | Samantha Brooks |
|---|---|
| Gender | Female |
| Speciality | Behavior Analyst |
| Location | 23 Hospital Dr Ste 102, Abilene, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508418658 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | 66624 (Texas) | Secondary |
| 103K00000X | Behavior Analyst | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Samantha Brooks, 23 Hospital Dr Ste 102, Abilene, TX 79606-5270 Ph: () - | Samantha Brooks, 23 Hospital Dr Ste 102, Abilene, TX 79606-5270 Ph: (325) 238-9337 |
News Archive
BioMedical Enterprises, Inc. (BME), has announced that on July 20th the Honorable Judge Laura Taylor Swain ordered that all proceedings in the patent infringement lawsuit between BME and InteliFUSE, Inc. be stayed pending the Court's disposition of a motion for summary judgment brought by BME.
BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX in the U.S. and Xiapex in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 ("miR-103/107") for the treatment of Non Alcoholic Steatohepatitis ("NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics.
One of the most promising new approaches to slowing the spread of HIV is pre-exposure prophylaxis (PrEP), a once-a-day medication that people who don't have HIV can take to prevent becoming infected.
MDMA (-3,4-methylenedioxymethamphetamine, also known as Ecstasy), may one day offer hope for individuals with posttraumatic stress disorder (PTSD), even people for whom other treatments have failed. Clinical trial results out today in the Journal of Psychopharmacology, published by SAGE, suggests that MDMA can be administered to subjects with PTSD without evidence of harm and could offer sufferers a vital window with reduced fear responses where psychotherapy can take effect.
› Verified 7 days ago